David Huang, MD, PhD, chief medical officer of Motif Bio, said, “We are delighted to have Stephanie join Motif. Her strategic insights, experience and leadership in late-stage global clinical trials and the regulatory process, including post-marketing requirements, make her ideally suited for this position. I am very excited and am looking forward to working with Stephanie as we continue to progress iclaprim towards an approval.”
05.09.18
Motif Bio announced that Stephanie Noviello, MD, MPH has joined the Company as vice president, Clinical Development. She will report to David Huang, MD, PhD, chief medical officer, and will be a key contributor to the European Marketing Authorisation Application submission for iclaprim.
Dr. Noviello joins Motif Bio from Bristol-Myers Squibb, where she most recently was clinical program lead, Virology. In this position, she served as clinical lead for the hepatitis B and C and HIV portfolios.
Dr. Noviello joins Motif Bio from Bristol-Myers Squibb, where she most recently was clinical program lead, Virology. In this position, she served as clinical lead for the hepatitis B and C and HIV portfolios.